Uncertainty for US Healthcare Reform following mid-term elections?

3 November 2010

Retaking of the House by Republicans in the mid-term elections in the USA brings uncertainty to the health care overhaul in the US, but it’s not all bad news, explains Datamonitor’s health care analyst Tijana Ignjatovic:

“The Republicans have vowed to repeal the health care reform law passed earlier in 2010, a key Obama policy, should they regain control in the US House of Representatives. However, although they have regained control in the House, with Democrats still in majority in the Senate, and with the White House supporting the reform, a repeal of the health care reform law is unlikely.

She goes on: “Nevertheless, Republicans could stall if not block the implementation of key reform measures by blocking appropriations funding for the least popular elements of the reform. As a result many healthcare lobby groups have already been lobbying for select measures to be removed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical